University of Sussex
Browse
fmc-2017-0062 lineham morley spencer.pdf (1.78 MB)

Dual abrogation of Mnk and mTOR; a novel therapeutic approach for the treatment of aggressive cancers

Download (1.78 MB)
journal contribution
posted on 2023-06-09, 06:29 authored by Ella Lineham, John SpencerJohn Spencer, Simon Morley
Targeting the translational machinery has emerged as a promising therapeutic option for cancer treatment. Cancer cells require elevated protein synthesis for cell growth and exhibit augmented activity to meet the increased metabolic demand. Eukaryotic translation initiation factor 4E (eIF4E) is necessary for mRNA translation, its availability and phosphorylation are regulated by the PI3K/AKT/mTOR and Mnk1/2 pathways, respectively. The phosphorylated form of eIF4E drives the expression of oncogenic proteins including those involved in metastasis. This article will review the role of eIF4E in cancer, its regulation, and discuss the benefit of dual-inhibition of upstream pathways. The discernible interplay between the Mnk1/2 and mTOR signaling pathways provides a novel therapeutic opportunity to target aggressive migratory cancers through the development of hybrid molecules.

Funding

The re-modelling of mRNPs and the regulation of localised mRNA translation during mammalian cell attachment and spreading; G1479; BBSRC; BB/L018209/1

History

Publication status

  • Published

File Version

  • Published version

Journal

Future Medicinal Chemistry

ISSN

1756-8919

Publisher

Future Science

Issue

13

Volume

9

Department affiliated with

  • Biochemistry Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2017-06-02

First Open Access (FOA) Date

2017-10-02

First Compliant Deposit (FCD) Date

2017-06-01

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC